Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ACTG GO-AHEAD IS PDL RAY OF SUNSHINE; BIOTECHS GET AUGUST BOUNCE FROM STREET

Executive Summary

Protein Design Lab's Protovir AIDS Clinical Trial Group 266 protocol is set to continue at a higher dose, thanks to a positive recommendation Sept. 3 from the ACTG. FDA, the National Institute of Allergy & Infectious Diseases and participating medical centers will need to concur with the recommendation. Enrollment in the 167-patient trial, which is about half complete, was halted pending approval of the higher dose
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028808

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel